Get started
Author

Catherine Shannon

Observed names: C M Shannon, C. Shannon, Catherine M Shannon, Catherine M. Shannon, Catherine Margaret Shannon, S. Catherine, Shannon, C, Shannon, Catherine
Observed institutions: Guy's Hospital, Translational Research Institute, Mater Health Services, Royal Adelaide Hospital, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, The University of Queensland, Brown University, Royal North Shore Hospital, The Royal Free Hospital, Princess Alexandra Hospital, Westmead Hospital, St Vincent's Hospital Sydney, Mater Research, Prince of Wales Hospital, Royal Marsden Hospital, MSD (Australia), Australia New Zealand Gynaecological Oncology Group, Mater Adult Hospital
ORCID: 0000-0002-2078-2869
Observed ORCID: 0000-0002-2078-2869
OpenAlex ID: A5029807906
Chemotherapy for Breast Cancer During Pregnancy: An 18-Year Experience From Five London Teaching Hospitals
2005 · Alistair E. Ring, Ian E. Smith, et al. · Journal of Clinical Oncology · 282
Breast cancer in adolescents and young women
2003 · C. Shannon, I.E. Smith · European Journal of Cancer · 190
Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status
1995 · Michael J. Glantz, Walter A. Hall, et al. · Cancer · 190
PDF
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
2020 · Jacobus Pfisterer, Catherine M Shannon, et al. · The Lancet Oncology · 171
PDF
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial
2021 · Yoland Antill, Peey-Sei Kok, et al. · Journal for ImmunoTherapy of Cancer · 138
PDF
VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results
2022 · Geoffrey J. Lindeman, Tharu M. Fernando, et al. · Clinical Cancer Research · 98
Does Timing of Adjuvant Chemotherapy for Early Breast Cancer Influence Survival?
2003 · C. Shannon, S. Ashley, et al. · Journal of Clinical Oncology · 84
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial
2024 · Christian Marth, Richard G. Moore, et al. · Journal of Clinical Oncology · 77
Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer
2016 · Brittney S Harrington, Yaowu He, et al. · British Journal of Cancer · 73
PDF
Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance
2015 · Y He, A C Wu, et al. · Oncogene · 61
Is there still a role for neoadjuvant therapy in breast cancer?
2002 · Catherine Shannon, Ian Smith · Critical Reviews in Oncology/Hematology · 60
Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).
2019 · Yoland Catherine Antill, Peey Sei Kok, et al. · Journal of Clinical Oncology · 56
Effect of a Standardized Ginger Root Powder Regimen on Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial
2023 · Megan Crichton, Skye Marshall, et al. · Journal of the Academy of Nutrition and Dietetics · 51
PDF
Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: Effective treatment of patients with poor prognostic features
2001 · C. Shannon, C. Crombie, et al. · Annals of Oncology · 51
Incidence of microsatellite instability in synchronous tumors of the ovary and endometrium.
2003 · Catherine Shannon, Judy Kirk, et al. · PubMed · 49
EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface
2014 · M N Adams, B S Harrington, et al. · Oncogene · 41
Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum‐sensitive recurrent ovarian cancer
2016 · Michael Friedlander, Susana Banerjee, et al. · Asia-Pacific Journal of Clinical Oncology · 39
PDF
Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO study group, AGO-Austria, ANZGOG, GINECO, SGCTG)
2018 · J. Pfisterer, A.P. Dean, et al. · Annals of Oncology · 35
Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).
2021 · Geoffrey J Lindeman, Rebecca Bowen, et al. · Journal of Clinical Oncology · 33
Occult primary breast carcinoma presenting as axillary lymphadenopathy
2002 · Catherine Shannon, Geraldine Walsh, et al. · The Breast · 33
REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer
2021 · Katrin M. Sjoquist, David Espinoza, et al. · Gynecologic Oncology · 30
Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601)
2019 · Y. Antill, P.S. Kok, et al. · Annals of Oncology · 30
PDF
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer
2026 · Sara A. Hurvitz, Rachel M. Layman, et al. · Journal of Clinical Oncology · 25
Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
2023 · Erika P. Hamilton, Jee Hyun Kim, et al. · Journal of Clinical Oncology · 25
PDF
Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical trials.
2021 · Sara A. Hurvitz, Haeseong Park, et al. · Journal of Clinical Oncology · 23
Works count: 106
Citation count: 2,322
H-index: 25
I10-index: 33
Year
Topic
Type